Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Revision History For: Alexion Pharmaceuticals, Inc. (ALXN)

No earlier versions found for this Subject.

Return to Alexion Pharmaceuticals, Inc. (ALXN)

I noticed Alexion when both Salomon and Robertson Stephens issued "strong buys" several weeks ago. In reviewing their portfolio, it appears that they are targeting the following areas: (a) Xenotransplantation, with U.S. Surgical as a partner, and with U.S. Surgical recently purchasing $3 million in ALXN at $17.97 (b) Cardiopulmonary disease, utilizing C5 Complement Inhibitors, with a succesful Phase I/II completed for cardiopulmonary bypass, and with pre-clinical work for myocardial infarction, and (c) Autoimmune disease, with what they refer to as Apogen T-Cell Therapeutics, with the intent to initially file an IND in '97 for MS, following strong pre-clinical data. With the conversion to stock from private placements, there are probabaly some 9 million shares outstanding. I am researching the company and am interested if anyone has an informed opinion as to the prospects for this company.